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Stability of the myelin-axon unit is achieved, at least in part, by specialized paranodal junctions comprised of the neuronal
heterocomplex of contactin and contactin-associated protein and the myelin protein neurofascin 155. In multiple sclerosis,
normal distribution of these proteins is altered, resulting in the loss of the insulating myelin and consequently causing
axonal dysfunction. Previously, this laboratory reported that mice lacking the myelin-enriched lipid sulphatide are characterized
by a progressive deterioration of the paranodal structure. Here, it is shown that this deterioration is preceded by significant loss
of neurofascin 155 clustering at the myelin paranode. Interestingly, prolonged electrophoretic separation revealed the existence
of two neurofascin 155 bands, neurofascin 155 high and neurofascin 155 low, which are readily observed following N-linked
deglycosylation. Neurofascin 155 high is observed at 7 days of age and reaches peak expression at one month of age, while
neurofascin 155 low is first observed at 14 days of age and constantly increases until 5 months of age. Studies using conditional
neurofascin knockout mice indicated that neurofascin 155 high and neurofascin 155 low are products of the neurofascin gene
and are exclusively expressed by oligodendrocytes within the central nervous system. Neurofascin 155 high is a myelin para-
nodal protein while the distribution of neurofascin 155 low remains to be determined. While neurofascin 155 high levels are
significantly reduced in the sulphatide null mice at 15 days, 30 days and 4 months of age, neurofascin 155 low levels remain
unaltered. Although maintained at normal levels, neurofascin 155 low is incapable of preserving paranodal structure, thus
indicating that neurofascin 155 high is required for paranodal stability. Additionally, comparisons between neurofascin 155
high and neurofascin 155 low in human samples revealed a significant alteration, specifically in multiple sclerosis plaques.
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Introduction
Axonal saltatory conduction is facilitated by the myelin sheath, a
lipid rich multi-lamellar wrap generated by oligodendrocytes in the
CNS. Throughout much of its length the mature sheath lacks cyto-
plasm resulting in compaction of the myelin membrane. At the
edges of the sheath, cytoplasm is retained in sacs known as para-
nodal loops (Peters et al., 1976). These loops ‘bend’ toward the
axonal membrane and establish septate-like junctions that main-
tain clusters of voltage-gated sodium and potassium channels at
the node of Ranvier and the juxtaparanode, respectively (Chiu,
1980; Waxman and Richie, 1985; Chiu and Schwarz, 1987;
Poliak and Peles, 2003; Rasband, 2004). These specialized junc-
tions are also critical in tethering the myelin sheath to the axon
through trans interactions between the myelin protein neurofascin
155 and the axonal heterocomplex of contactin and
contactin-associated protein (Caspr) (Rios, 2000; Tait et al.,
2000; Bhat et al., 2001; Boyle et al., 2001; Charles et al.,
2002). Although the specifics of the interactions between neuro-
fascin 155 and contactin/Caspr remain unresolved (Gollan et al.,
2003; Bonnon et al., 2007), it is clear that mice lacking either
contactin, Caspr or neurofascin 155 fail to form the paranodal
septate-like junctions, do not properly establish paranodal and
juxtaparanodal protein domains (Bhat et al., 2001; Boyle et al.,
2001; Sherman et al., 2005; Zonta et al., 2008, Pillai et al., 2009),
and exhibit compromised paranodal loop orientation (Bhat et al.,
2001). Whereas compromised paranode formation and stability
are consistent with the absence of either contactin, Caspr or neu-
rofascin 155, it is more difficult to reconcile the loss of paranode
structure in mice that lack netrin-1 or deleted in colorectal cancer
(DCC) (Jarjour et al., 2008), myelin and lymphocyte (MAL) pro-
tein (Schaeren-Wiemers et al., 2004), galactocerebroside and sul-
phatide (Dupree et al., 1998) or sulphatide alone (Honke et al.,
2002). Paranodal deterioration, reminiscent of these mutant mice,
also occurs in multiple sclerosis, prior to demyelination, as para-
nodal loops face away from the axon (Suzuki et al., 1969), para-
nodal clustering of Caspr and neurofascin 155 is reduced
(Wolswijk and Balesar, 2003; Howell et al., 2006), and juxtapar-
anodal proteins invade the paranode (Howell et al., 2006).
Interestingly, in addition to reporting a possible reduction of sul-
phatide in normal-appearing white matter in patients with multiple
sclerosis, Marbois et al. (2000) showed a significant alteration in
the sulphatide species present in multiple sclerosis. These findings
emphasize the need to elucidate further the role of sulphatide in
the regulation of paranode stability.
The sulphatide null mice, which contain a disruption in the
gene that encodes the enzyme cerebroside sulphotransferase
(CST) (Honke et al., 1996, 1997), initially form abundant, com-
pacted myelin sheaths and structurally normal nodes and para-
nodes; however, with age the CST knockout mice reveal a loss
of myelin sheath compaction, altered paranodal loop orientation,
increased nodal length (Marcus et al., 2006), and a reduction of
nodal protein domains (Ishibashi et al., 2002). In the present
study, quantitative analysis advances the previous observation of
neurofascin 155 cluster loss (Marcus et al., 2006), while western
blot analysis indicates that the loss of neurofascin 155 clusters
does not result strictly from decreased neurofascin 155 levels.
Equally important, the current study demonstrates that neurofascin
155 is comprised of two forms, termed neurofascin 155 high
(155H) and neurofascin 155 low (155L). It is shown here that
neurofascin 155H and neurofascin 155L are oligodendrocyte-
specific products of the neurofascin (Nfasc) gene that differ with
regard to N-linked glycosylation and temporal expression.
Neurofascin 155H is a paranodal protein whose levels are reduced
in CST knockout mice and is nearly absent by 4 months of age. In
contrast, levels of neurofascin 155L are not altered in the CST
knockout mice as compared to littermate wild-type animals.
With age in both genotypes, neurofascin 155L becomes more
abundant and less glycosylated. However, its function remains
unknown. Evaluation of human brain samples showed a multiple
sclerosis plaque-specific alteration between neurofascin 155H and
neurofascin 155L following deglycosylation. These results indicate
that, in both mouse and human samples, the expression pattern of




Wild-type and CST knockout (Honke et al., 2002), also known as
sulphatide null, mice were genotyped as described (Shroff et al.,
2009). Other animals used in this study include Caspr knockout
(Bhat et al., 2001), neurofascin conditional knockout, referred to as
CNP-Cre;Nfascflox/flox, (Pillai et al., 2009), and littermate wild-type
mice. Sprague-Dawley rats were purchased from Charles River
Laboratories (Wilmington, MA, USA). Animal use was conducted in
accordance with the guidelines from the National Institutes of Health
and approved by the Virginia Commonwealth University’s Animal Care
and Use Committee.
Antibodies
The neurofascin antibodies used in this study have been previously
characterized and are known as FIGQY (Ogawa et al., 2006) and
NF-C1 (Tait et al., 2000). For immunocytochemical labelling of
frozen tissue sections, FIGQY and NF-C1 were used at 1:200 and
1:1000 dilutions, respectively. For western blot analysis, both antibo-
dies were diluted 1:2000. These antibodies are directed against distinct
epitopes of the cytoplasmic tail common to neuronal neurofascin
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186, oligodendrocyte neurofascin 155, and the uncharacterized pro-
tein neurofascin 140. Other antibodies used in this study include:
anti-Caspr (1:1000; Bhat et al., 2001); anti-pan voltage gated
sodium channel (1:200; Sigma-Aldrich, St Louis, MO, USA); anti-
extracellular signal-regulated kinase 2 (1:10 000; Santa Cruz
Biotechnology, Santa Cruz, CA,USA); anti-myelin basic protein
(1:100; Millipore, Billerica, MA); anti-20, 30-cyclic nucleotide
30-phosphodiesterase (CNP; 1:1000, Covance, Emeryville, CA); horse-
radish peroxidase conjugated secondary antibodies (1:10 000; Santa
Cruz); and fluorescently conjugated secondary antibodies (1:200;
Vector Laboratories, Burlingame, CA, USA).
Immunocytochemistry
Cervical spinal cord samples from three wild-type and four littermate
CST knockout mice at 15 and 30 days of age and a rat at 7 days of
age were single, double or triple labelled as previously described
(Dupree et al., 1999; Marcus et al., 2006).
Quantitation of Nfasc 155 localization
Immunolabelled sections were analysed using a Leica TCS2 AOBS laser
scanning confocal microscope. Maximum projection images were com-
piled using eight optical sections spanning 3.6 mm and collected using
a pin hole of one Airy unit with a resolution of 10241024 pixels.
All images were collected using a PL APO 63oil immersion objective
lens (numerical aperture of 1.4–0.7) with a digital zoom of two result-
ing in a microscopic field of 119mm 119mm. To ensure that similar
regions of the cervical cord were sampled, the cerebellum was used to
discern ventral and dorsal columns. All images were collected from the
cervical ventral columns. The posterior portion of the cerebellum was
also used as the most anterior extent of the spinal cord and thus
served as the starting point for image collection. For quantitation, six
maximum projection images per section were collected; neurofascin
155 paranodal clusters were counted, and the average number of
clusters per image was determined for each mouse. Two sets of criteria
were used to identify paired neurofascin 155-containing paranodes.
First, solid rectangular clusters ranging between 5 and 15mm with
well demarcated ends were identified as a single paranodal pair (see
Supplementary Fig. 2A’ and B’). Second, paired rectangular clusters
(corresponding to two adjacent paranodes) separated by a small
region void of labelling (corresponding to the node of Ranvier) were
also identified as a single paranodal pair (Supplementary Fig. 2C’).
Unpaired clusters were not counted (Supplementary Fig. 2D’). All
counts were statistically compared using two-tailed t-tests and signif-
icance was defined as P50.05.
Western blot analysis
Animals were deeply anaesthetized with 2, 2, 2-tribromoethanol
(Sigma-Aldrich); brain and spinal cord were dissected, rapidly frozen
separately in liquid nitrogen, and stored at 80C. Homogenization
utilized a Glas-Col (Terre Haute, IN, USA) motor-driven homogenizer,
a Potter Elvehjem mortar, and a Teflon pestle (Wheaton Industries,
Inc., Millville, NJ, USA). Tissues were homogenized (5 min per brain
and 3 min per spinal cord) on ice in modified radioimmunoprecipitation
assay buffer [137 mM NaCl, 10 mM Na2HPO4, 1.8 mM KH2PO4,
2.7 mM KCl, pH 7.4 with 0.1% sodium dodecyl sulphate (SDS),
0.5% sodium deoxycholate, 0.1% nonidet P-40] with protease inhib-
itor cocktail [Sigma-Aldrich P8340, comprised of 4-(2-aminoethyl)-
benzenesulphonyl fluoride, pepstatinA, E-64, bestatin, leupeptin and
aprotinin] followed by centrifugation for 1 min at 16 100g in a table
top microcentrifuge. Supernatant concentrations were determined
using the Micro BCA Protein Assay Kit (Pierce, Rockford, IL, USA).
Twenty–thirty micrograms of spinal cord or 40–50 mg of brain proteins
in Laemmli sample buffer (Bio-Rad, Hercules, CA, USA) containing
5% b-mercaptoethanol were subjected to SDS–polyacrylamide gel
electrophoresis for 30 min at 70 V followed by either 40 or 150 min
(see below) at 180 V using 10% Ready Gels (Bio-Rad). Precision Plus
Protein Kaleidoscope Standards (Bio-Rad) allowed monitoring of the
gel run and transfer. For the extended electrophoresis protocol, the
electrophoresis was allowed to proceed until the 75 kDa standard band
reached the bottom of the gel (150 min) and transferred to nitrocel-
lulose for 2 h at 100 V. The membranes were then blocked with 5%
non-fat dry milk (Bio-Rad) in phosphate buffered saline containing
0.05% Tween 20 (Sigma-Aldrich) prior to incubation with primary
and secondary antibodies, and the same solution was utilized for anti-
body incubations. Immunoreactive bands were visualized with horse-
radish peroxidase chemiluminescent substrate (Pierce or Millipore,
Billerica, MA, USA) and either an Alpha Innotech FluorChem SP
imager (San Leandro, CA, USA) or radiograph film.
Glycosidase reaction
Peptide N-glycosidase F (PNGase F) and related reagents were
obtained from New England Biolabs (Ipswich, MA, USA). Following
the manufacturer’s suggested protocol, a typical 25 ml reaction
included 50 mg of protein, 2 ml of PNGase F (1000 U, as defined
by the manufacturer), and 1 ml of protease inhibitor cocktail (Sigma-
Aldrich, P8340). Following 3 h at 37C, samples were mixed with one
volume of Laemmli Sample Buffer containing 5% b-mercaptoethanol
and prepared for SDS–polyacrylamide gel electrophoresis as above.
Densitometry, molecular mass and
glycosylation analyses
Except where stated otherwise, protein band densities were measured
with the AlphaEase software version 4.1.0 by Alpha Innotech
Corporation. All western blot densities were normalized to extracellular
signal-regulated kinase 2, data were analysed by a two-tailed t-test,
and significance was defined as P50.05. The same software was
paired with Magic Mark XP Western Protein Standard (Invitrogen,
Carlsbad, CA, USA) to determine molecular masses and shifts due to
deglycosylation utilizing the 220, 120, 100 and 80 kDa bands of the
PNGase F treated and untreated samples.
For the quantitative analysis shown in Fig. 8, ImageJ 1.14o was
utilized to determine the density of a rectangular selection encompass-
ing neurofascin 155H’ and neurofascin 155L’ (neurofascin’ refers to
deglycosylated neurofascin). The resulting graphical plot was observed
to contain either one or two peaks and the area under the curve was
determined with the wand tool. In the case of one peak, the straight
line selection function was utilized to divide the plot into the main
region corresponding to the neurofascin 155H’ band and the lesser
region corresponding to the shadow-like neurofascin 155L’ band. The
area under each curve was then determined as above. In the case of
two peaks, the wand tool was utilized to divide the plot into two
regions, corresponding to neurofascin 155H’ and neurofascin 155L’.
For examples of this procedure and representative plots of
non-multiple sclerosis and multiple sclerosis plaque samples, see
Supplementary Fig. 3. The density values obtained from this analysis
were first utilized to create a ratio of neurofascin 155H’/neurofascin
155L’ for each sample. These ratios were then grouped as
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non-multiple sclerosis and normal-appearing white matter versus mul-
tiple sclerosis plaque, and compared using a two-tailed Student’s t-test
with unequal variance. Multiple sclerosis sample 119 was removed
from quantitative analysis due to a Cook’s distance value 41, calcu-
lated with the Predictive Analytics SoftWare Statistics 17.0 software,
indicating that a data point is an outlier and therefore a candidate for
removal from the data set (Cook, 1977); it is noteworthy that this
patient with confirmed multiple sclerosis died of complications due
to leukaemia and suffered multiple brain haemorrhages.
The NetNGlyc Server 1.0 (http://www.cbs.dtu.dk/services/
NetNGlyc/) was used to predict locations of N-linked glycosylation
(PubMed accession AAL27854, rat neurofascin 155 kDa isoform) as
well as the likelihood that a given site is glycosylated in vivo.
‘Highly likely’ is defined as above 0.5 threshold, 9/9 neural networks
agreeing on the outcome, and a ++ result. ‘Somewhat likely’ is defined
as above 0.5 threshold, 6 or more neural networks agreeing on the
outcome, and a + result. Both likelihoods were considered to be poten-
tial sites of glycosylation. Only NXS/T sequons free of proline and
located in the extracellular region were considered. Molecular mass
was calculated with the ExPASy ‘Computer pI/MW’ tool available
at www.expasy.ch/tools/pi_tool.html.
Human samples
Human brain samples from non-multiple sclerosis and multiple sclerosis
donors (both plaque and normal-appearing white matter) were pro-
vided by the Rocky Mountain Multiple Sclerosis Centre (Englewood,
CO, USA). All samples were collected at time of autopsy, which was
between one and 9 h post-mortem. At the time of death, donors
ranged between 30 and 87 years of age. All samples were collected
from sub-cortical white matter regions and immediately snap frozen in
liquid nitrogen. Based on medical history and autopsy evaluation, none
of the multiple sclerosis individuals included in this study presented
any neurodegenerative disorders other than multiple sclerosis. Brains
were classified as ‘multiple sclerosis’ or ‘non-multiple sclerosis’ based
on medical history and post-mortem pathological analyses at both the
macroscopic and light microscopic levels. Macroscopic analysis
revealed well circumscribed, grey, glistening depressed plaques only
in multiple sclerosis samples. Microscopic analysis was used to assess
myelin pallor and cellularity. Using this combination of evaluations, all
disease tissue samples used in this study were collected from con-
firmed multiple sclerosis cases.
Extent of cellularity was used to classify multiple sclerosis plaque
samples further as ‘active’ versus ‘inactive’. Active multiple sclerosis
samples exhibited hypercellularity demonstrated by lymphocytes,
macrophages and/or reactive astrocytes. In contrast, inactive plaques
were identified by the absence of hypercellularity. All multiple sclerosis
samples were collected within the lesion site whereas normal appear-
ing white matter samples were collected from brains with confirmed
multiple sclerosis but from regions that appeared normal based on
macroscopic and microscopic evaluation. For specific age, gender,
post-mortem harvest times and pathologic summary of each donor
used in this study, see Table 1.
For analysis within this study, non-multiple sclerosis (n = 4), normal
appearing white matter from multiple sclerosis donors (n = 5) and mul-
tiple sclerosis plaque samples from active (n = 4) and inactive (n = 5)
lesions were evaluated. An 21 cm sample was collected from the
received sub-cortical white matter samples and processed for western
blot and deglycosylation analyses as described above with 20–25 mg
of protein per lane.
Results
Paranodal clusters of neurofascin
155 are significantly reduced in CST
knockout mice
The NF-C1 pan-neurofascin antibody was utilized to quantify
paranodal clusters of neurofascin 155 in the ventral columns of
Table 1 Donor information for the Rocky Mountain Multiple Sclerosis Centre brain samples used in this study
Disease summary No. Age Gender HTTC Pathological evaluation of the brain
Non-MS 2 63 – 9 Myelin stain revealed no evidence of MS
Non-MS 5 55 F 2 No plaques observed in coronal sections
Non-MS 27 65 M 6.5 History of myocardial infarction
Non-MS 32 70 F 8 No plaques observed in multiple brain regions
NAWM-MS 243a 58 F 5 Numerous shadow plaques in PVWM
NAWM-MS 216a 71 F 4.5 Numerous plaques with near total myelin loss
NAWM-MS 235 41 F 3 Neurons preserved, no anoxic injury; cavitation
NAWM-MS 237 50 M 4 PVWM extensively demyelinated, no anoxic injury
NAWM-MS 137a 30 M 5 Grossly visible plaques in multiple regions
Active MS 137a 30 M 5 Grossly visible plaques in multiple regions
Active MS 73 44 M 4 Myelin pallor and shadow plaques throughout
Active MS 136 43 F 3.5 PVWM extensively demyelinated, hypercellularity
Active MS 168 37 F 3.5 PVWM extensively demyelinated
Inactive MS 119 38 F 1 12 year history of multiple sclerosis
Inactive MS 164 – – 3 Axons present in demyelinated regions
Inactive MS 224 87 F 4 Myelin pallor in frontal and parietal lobes
Inactive MS 243a 58 F 5 Numerous shadow plaques in PVWM
Inactive MS 216a 71 F 4.5 Numerous plaques with near total myelin loss
Averages and totals 52.1 9 F, 4 M 4.5
18 samples 2 NA
MS = multiple sclerosis; HTTC = hours to tissue collection; PVWM = periventricular white matter; NAWM = normal appearing white matter; = data not available (NA).
aTwo samples (normal appearing white matter and plaque) from the same donor.
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wild-type and CST knockout mice at 15 and 30 days of age
(Fig. 1; see Supplementary Fig. 1 for colour). At both ages,
wild-type mice exhibited numerous paranodal clusters of neuro-
fascin 155 (Fig. 1A, C and E; Table 2). While paranodal clusters of
neurofascin 155 were also observed in the CST knockout mice,
comparison with the wild-type mice indicated significant reduc-
tions at each age examined (for an explanation of how the clusters
were defined and quantified, see the ‘Materials and methods’
section). In 15-day-old CST knockout mice, the number of para-
nodal clusters of neurofascin 155 was reduced by 50% and by
30 days of age the CST knockout mice contained fewer than 10%
of the number of clusters observed in littermate wild-type mice
(Fig. 1B, D and E; Table 2). Similar observations were made with
the FIGQY pan-neurofascin antibody (data not shown).
Additionally, the 30-day-old CST knockout mice showed a preva-
lence of small, unpaired clusters (Fig. 1D, Supplementary Fig. 2D’).
Double labelling with a sodium channel antibody (data not shown)
revealed that the unpaired clusters were at the node of Ranvier,
consistent with the distribution of neurofascin 186 (Tait et al.,
2000).
Levels of neurofascin 155 are
significantly reduced in spinal cords
of CST knockout mice
The reduced paranodal clusters of neurofascin 155 observed in the
CST knockout mice could result from either decreased protein
expression or improper protein localization. To discern between
these two possibilities, the levels of neurofascin 155 were deter-
mined by western blot analysis. Figure 2A shows that, compared
to littermate wild-type mice, neurofascin 155 was reduced by
40% in the spinal cords of 15- and 30-day-old CST knockout
mice (Fig. 2D; Table 2). However, as shown in Fig. 2B and C, the
decrease in neurofascin 155 is not accompanied by a
widespread reduction of myelin proteins as neither levels nor
developmental expression patterns of the myelin-specific proteins
CNP or myelin basic protein was altered in the CST
knockout mice.
Extended electrophoresis reveals that
neurofascin 155 is comprised of two
bands—neurofascin 155 high and
neurofascin 155 low
Consistent with previous studies (Schafer et al., 2004; Sherman
et al., 2005), standard electrophoretic separation (40 min; see
‘Materials and methods’ section) of spinal cord homogenates
from wild-type mice up to 30 days of age resulted in the detection
of a single band representing neurofascin 155 (Fig. 2A). However,
extended electrophoresis of the same samples revealed two bands,
now named neurofascin 155 high (155H) and neurofascin 155
low (155L), at 30 days of age in the CST knockout mice
(Fig. 3A–C) as well as in the wild-type brain (Fig. 3C) between
neurofascin 186 and neurofascin 140. Neurofascin 155L was not
detected by extended electrophoresis at 15 days of age in either
wild-type or CST knockout animals. Neurofascin 155H and neu-
rofascin 155L were detected by the pan-neurofascin antibodies
FIGQY (Fig. 3A and C, and all other figures unless otherwise
stated) and NF-C1 (Fig. 3B), and were present in both spinal
cord (Fig. 3A and B) and brain (Fig. 3C) homogenates.
Figure 1 Paranodal clustering of neurofascin 155 is significantly
reduced in the absence of sulphatide. Cervical spinal cord
sections immunolabelled with the NF-C1 pan-neurofascin anti-
body revealed abundant paired clusters of neurofascin (Nfasc)
155 in the myelin paranode of wild-type (WT) animals at 15 (A)
and 30 (C) days of age. Note that the labelling pattern in the
15-day-old animals was frequently rectangular in shape repre-
senting immunolabelling of both neurofascin 155 in the myelin
paranode and neurofascin 186 in the (axonal) node. In contrast,
by 30 days of age, nodal labelling was less apparent while
paranodal labelling remained prevalent. In the CST knockout
(KO) spinal cord sections, the number of paranodal clusters of
neurofascin 155 was reduced by 50 and 90% at 15 (B) and 30
(D) days of age, respectively, compared to littermate wild-type
mice. Also, note that by 30 days of age, the prevalence of small,
single clusters (arrows) was increased in the CST knockout.
(E) Quantitative analyses revealed that the reduction of para-
nodal clustering of neurofascin 155 was significantly reduced at
both 15 and 30 days of age. Scale bar = 10 mm; see Table 2.
P50.05.
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Neurofascin 155H and neurofascin
155L are distinctly regulated through
development
To examine whether the observations of Fig. 3 were specific to
mouse and to determine the expression profiles of neurofascin
155H and neurofascin 155L in wild-type animals, spinal cord
homogenates from rats ranging between 7 days and 5 months
of age were separated by the extended electrophoresis protocol
(Fig. 4A). Neurofascin 155H was visible at all ages, increasing in
intensity from barely detectable at 7 days to maximal levels at
27 days of age, followed by a reduction at 3 and 5 months.
Figure 2 CST knockout spinal cords contain reduced amounts
of neurofascin 155 at 15 and 30 days of age. (A) Western blot
analysis showed that CST knockout (KO) mice contain 40%
less (Table 2) neurofascin (Nfasc) 155 at 15 and 30 days of age
than wild-type (WT) littermates. However, no change in the
levels of either the CNP monomers (B) or myelin basic proteins
(MBP) (C) was observed in the absence of sulphatide, demon-
strating that the reduction in neurofascin 155 is not due to a
global decrease in myelin proteins. (D) Graphical representation
of the reduction in neurofascin 155. ERK2 = extracellular signal-
regulated kinase 2. P50.05.
Figure 3 Extended electrophoresis reveals two forms of
neurofascin 155. At 15 days of age, the FIGQY (A) and NF-C1
(B) pan-neurofascin antibodies labelled one band representing
neurofascin (Nfasc) 155 in both the wild-type (WT) and the CST
knockout (KO) spinal cord samples. By 30 days of age, wild-type
samples displayed the protein now called neurofascin 155H with
a shadow-like band immediately below, while the CST knockout
samples showed both neurofascin 155H and neurofascin 155L.
(C) Mouse brain samples incubated with FIGQY show neuro-
fascin 155H and neurofascin 155L in both wild-type and CST
knockout at 30 days of age and, when compared to 15-day-old
samples, suggest a developmental pattern for neurofascin 155L
in wild-type as well as CST knockout mice. ERK2 = extracellular
signal-regulated kinase 2.
Table 2 Neurofascin paranodal clusters and protein in the CST knockout spinal cord
Age Wild-type (n) SD Knockout (n) SD P Reduction (%)
Neurofascin 155 positive clusters/field
15 days 75.4 (3) 14.1 36.8 (4) 8 0.0001 51.2
30 days 118.6 (3) 51.1 9.5 (4) 9.3 0.001 92.2
Neurofascin 155 (protein), % of wild-type
15 days 100 (3) 3.90% 64.2 (4) 13.80% 0.001 35.8
30 days 100 (4) 17.00% 60.9 (2) 15.80% 0.027 39.1
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Figure 4 Neurofascin 155H and neurofascin 155L are developmentally regulated glycoproteins in rat spinal cord. (A) Rat spinal cord
homogenates revealed low levels of neurofascin 155H at 7 days of age. Neurofascin 155H steadily increased with age, reaching a peak at
27 days of age followed by a decrease which is maintained through 5 months of age. Neurofascin 155L was first seen as a clearly
delineated band at 3 months of age and remained prevalent at 5 months. Interestingly, neurofascin 155L appeared to form gradually from
the shadow-like band below neurofascin 155H. (B) Following PNGase F treatment neurofascin 155L’ was observed in 3 and 5 month
samples (as expected from Fig. 4A) as well as at 14, 21 and 27 days of age, with increasing abundance with increasing age. Neurofascin
155H’ was barely visible at 7 days of age, became increasingly intense through 27 days of age, then decreased in abundance at 3 and 5
months of age consistent with neurofascin 155H in Fig. 4A. (C) At 7 days of age, when neurofascin 155L’ was not present, the
pan-neurofascin antibody FIGQY labelled neurofascin 186 at the node of Ranvier and neurofascin 155H at the paranode in the rat spinal
cord. Voltage gated sodium channels are indicated in dark blue (a and e), Caspr is indicated in red (b and f), and FIGQY labelling is shown
in green (c and g). The panels on the left (a–d) show a fully formed node:paranode region and in the merged image (d) light blue
represents voltage gated sodium channels and neurofascin 186 at the node and the flame colour represents Caspr and neurofascin 155H
at the paranode. The panels on the right (e–h) show an immature node:paranode region with a pair of voltage gated sodium channel/
neurofascin 186-labelled clusters flanking an unlabelled region that is presumed to develop into the node. Notice that the flame colour
is observed in the merged image (h) indicating that Caspr and neurofascin 155H are present in the developing paranode. d = days;
m = months; P = PNGase F treated; ERK2 = extracellular signal-regulated kinase 2; Nfasc = neurofascin; Nav = voltage gated sodium.
Scale bar = 5mm.
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An increasingly dark shadow-like band, perhaps representing mul-
tiple glycosylation states, was present immediately below neuro-
fascin 155H beginning at 14 days of age. By 3 months of age the
shadow-like band was no longer visible but a distinct neurofascin
155L band was observed and remained prominent until at least
5 months of age.
Neurofascin 155H and neurofascin 155L
contain N-linked carbohydrates
Previous work (Volkmer et al., 1992; Davis et al., 1993; Maier
et al., 2005) has shown that neurofascin proteins are glycosylated
and analysis with the NetNGlyc 1.0 Server indicated that neuro-
fascin 155 contains multiple (predicted) sites for N-linked glycosy-
lation. To test the possibility that neurofascin 155H and
neurofascin 155L are the same polypeptide that differ according
to the extent of N-linked glycosylation, samples were treated with
PNGase F, which specifically removes N-linked carbohydrates
without compromising peptide bond integrity (Maley et al.,
1989). If the molecular mass difference between neurofascin
155H and neurofascin 155L resulted exclusively from N-linked
glycosylation, then a single, faster migrating band would be
detected following PNGase F treatment. Interestingly, following
N-linked deglycosylation, neurofascin 155H and neurofascin
155L remained as distinct bands (Fig. 4B; see Fig. 6A for
side-by-side untreated and treated lanes). The bands resulting
from PNGase F treatment are referred to as neurofascin 155H’
and neurofascin 155L’ to acknowledge that neurofascin 155H
and neurofascin 155L exist in vivo while neurofascin 155H’ and
neurofascin 155L’ are generated by in vitro deglycosylation.
Unexpectedly, PNGase F treatment revealed neurofascin 155L’
from samples of 14, 21 and 27-day-old animals, as well as at the
expected ages of 3 and 5 months (Fig. 4B). This transition from
shadow-like band to distinct band, possibly due to variable,
age-related states of glycosylation (see ‘Discussion’ section), sug-
gested that neurofascin 155L was the source of the increasingly
dark shadow-like band observed in Fig. 4A. Fig. 4B shows that
neurofascin 155H’ increases steadily between 7 and 27 days of
age before sharply decreasing between 27 days and 3 months of
age. This temporal pattern of expression of neurofascin 155H’ is
consistent with neurofascin 155H playing a role in myelination, as
has been previously shown for neurofascin 155 (Collinson et al.,
1998). In contrast, neurofascin 155L’, which was not detected at 7
days of age, first appeared in the rat spinal cord between 7 and 14
days of age and steadily increased in abundance through 5
months of age. The slowly increasing abundance of neurofascin
155L’ suggested that, unlike neurofascin 155H, neurofascin 155L
does not play a role in the initial stages of myelination.
Neurofascin 155H is a component
of the myelin paranode
Since neurofascin 155L was not detected in 7-day-old rat spinal
cord (Fig. 4A and B), this age provided the opportunity to deter-
mine the localization of neurofascin 155H. As shown in Fig. 4C,
the localizations of voltage gated sodium channels and Caspr are
used to identify the nodal and paranodal domains, respectively, in
established [Fig. 4C, (a–d)] and developing [Fig. 4C, (e–h)]
node:paranode regions. The unlabelled region between the
labelled clusters in Fig. 4C (e–h) is consistent with the developing
node:paranode region described by Shrager and colleagues
(Dugandzija-Novakovic et al., 1995). In both series of images,
the FIGQY pan-neurofascin antibody strongly labels the nodal
and paranodal regions. Paranodal reactivity against the FIGQY
pan-neurofascin antibody at an age when neurofascin 155L is
not detected by western blot analysis indicates that neurofascin
155H is the myelin paranodal protein previously referred to as
neurofascin 155 (Tait et al., 2000; Poliak and Peles, 2003).
Neurofascin 155H and neurofascin
155L are products of the Nfasc gene
Bhat and colleagues recently reported the generation of a mouse
line with a floxed Nfasc transgene that is removed via CNP
promoter-regulated Cre expression (CNP-Cre;Nfascflox) (Pillai
et al., 2009). Since CNP promoter activity in the CNS has been
shown to be exclusive to oligodendrocytes (Trapp et al., 1988),
these mice allow for specific deletion of the Nfasc gene from
oligodendrocytes. CNP-Cre;Nfascflox/flox mice die by 17 days of
age; accordingly, spinal cords were harvested from 16-day-old
wild-type (+/+), CNP-Cre/Nfasc+/flox (heterozygote) and
CNP-Cre;Nfascflox/flox (homozygote) mice and are shown in
Fig. 5A and B. Both wild-type and CNP-Cre;Nfasc+/flox samples
exhibited the normal pattern of neurofascin 155H plus the
shadow-like band, together termed neurofascin 155H&L, prior to
PNGase F treatment (Fig. 5A) and both neurofascin 155H’ and
Figure 5 Neurofascin 155H and neurofascin 155L are
products of the Nfasc gene. Spinal cords from 16-day-old
CNP-Cre;Nfascflox/flox mice contained no ‘neurofascin 155H&L’
and no neurofascin 155H’ or neurofascin 155L’ (arrows) when
observed without (A) or with (B) PNGase F treatment.
ERK2 = extracellular signal-regulated kinase 2.
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neurofascin 155L’ after PNGase F treatment (Fig. 5B). In contrast,
neither neurofascin 155H/neurofascin 155H’ nor neurofascin 155L/
neurofascin 155L’ were observed in the CNP-Cre;Nfascflox/flox sample
(arrows). These results demonstrate that both neurofascin 155H and
neurofascin 155L are products of the Nfasc gene and suggest that
both neurofascin 155H and neurofascin 155L are exclusively
expressed by oligodendrocytes since expression is eliminated by
CNP promoter-regulated Cre expression.
Neurofascin 155H, but not neurofascin
155L, is reduced in the absence of
sulphatide
The combined results of Figs 3 and 4 suggest that the levels of
neurofascin 155H’ and neurofascin 155L’ could be differentially
altered in the CST knockout mice. Accordingly, PNGase F was
employed to quantitatively compare levels of neurofascin 155H’
and neurofascin 155L’ in the wild-type and CST knockout mice.
As shown in Fig. 6A, PNGase F treated spinal cord samples from
CST knockout mice contain 50% less neurofascin 155H’
than wild-type littermates at 15 and 30 days of age (Fig. 6B;
Table 3). In contrast, neurofascin 155L’ was not reduced at
either 15 or 30 days of age (Fig. 6C; Table 3). At 4 months of
age, neurofascin 155H’ was also significantly reduced and no
definitive band was observed for neurofascin 155H’ (or neurofas-
cin 155H) in the CST knockout spinal cords, while the amount
of neurofascin 155L’ remained unchanged (Fig. 6C; Table 3).
Running the untreated and PNGase F treated samples side-by-side
facilitates the comparison of the shifts in migration induced by
deglycosylation. Note that neurofascin 155L was not observed in
Figure 6 Neurofascin 155H’ is reduced in CST knockout spinal cords. (A) Following PNGase F treatment, spinal cord homogenates
showed an 50% decrease in neurofascin 155H’ at 15 and 30 days of age. Surprisingly, at 4 months of age no definitive neurofascin
155H’ (or neurofascin 155H) band was observed in the CST knockout samples (arrow). Quantitative analyses revealed that neurofascin
155H’ (B) was significantly reduced in the CST knockout mice at all ages examined while the levels of neurofascin 155L’ (C) were not
altered; see Table 3. = untreated; P = PNGase F treated; KO = knockout; WT = wild-type; Nfasc = neurofascin; ERK2 = extracellular
signal-regulated kinase 2. P50.05.
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the untreated lanes at 15 days of age from either genotype or in
the 30 day wild-type sample; however, following PNGase F treat-
ment, neurofascin 155L’ was clearly distinguished in these lanes,
consistent with the idea that the band labelled ‘neurofascin
155H&L’ contains both proteins, and that neurofascin 155L is
variably glycosylated with age. For this reason, only neurofascin
155H’ and neurofascin 155L’ were quantified. Age-dependent
extinction of the neurofascin 155H band is not a normal event,
as neurofascin 155H (and neurofascin 155L) have been observed
in spinal cord homogenates from wild-type mice as old as
22 months of age (data not shown).
Reduced levels of neurofascin 155H
are not limited to the CST
knockout mice
To determine whether there is a relationship between reductions
in neurofascin 155H/neurofascin 155H’ and paranodal stability,
Caspr knockout mice (Bhat et al., 2001) were analysed via
PNGase F treatment and the extended electrophoresis protocol.
These mice, reminiscent of the CST knockout mice, exhibit abnor-
mal paranodes and lack septate-like paranodal junctions. The life
expectancy of these mice is 421 days (Bhat et al., 2001), so
analysis was restricted to younger ages. Similar to 15-day-old
CST knockout mice, 19-day-old Caspr knockout mice revealed
noticeably reduced levels of neurofascin 155H and neurofascin
155H’, while levels of neurofascin 155L and neurofascin 155L’
were only modestly altered (Fig. 7). This reduction in neurofascin
155H and neurofascin 155H’, taken together with the findings
from the CST knockout mice, suggests that the loss of neurofascin
155H may be a general defect associated with paranodal
instability.
The pattern of neurofascin 155H and
neurofascin 155L is altered in
multiple sclerosis plaques
Analysis of human brain samples by the extended electrophoresis
protocol (Figure 8A1) indicated that neurofascin 155H is abundant
in non-multiple sclerosis brain samples while no clearly delineated
neurofascin 155L was observed. (‘Clearly delineated’ refers to a
band that is distinct and separate from adjacent bands.) A similar
banding pattern was observed in brain samples taken from regions
of white matter that appear normal in multiple sclerosis brains
(normal-appearing white matter). Normal-appearing is defined as
revealing no visible signs of myelin deterioration as determined by
both macroscopic and light microscopic examination. All multiple
sclerosis plaque samples also revealed neurofascin 155H. However,
samples from two (#164 and 224) of the eight donors analysed
revealed a band with an apparent molecular mass consistent with
neurofascin 155L as identified in rodent. To assess this possible
alteration better, multiple sclerosis plaque samples were run
side-by-side with either non-multiple sclerosis or normal-appearing
white matter-multiple sclerosis samples (representative examples
are presented in Figs 8A2 and Figure 8A3, respectively). This addi-
tional analysis further indicated that the banding pattern for neu-
rofascin 155H and neurofascin 155L was altered in certain
samples, with clearly delineated neurofascin 155L being observed
only in multiple sclerosis plaque samples.
Figure 7 Spinal cords from Caspr knockout mice, similar to CST
knockout animals, contain reduced amounts of neurofascin
155H and neurofascin 155H’. Comparable to 15-day-old CST
knockout mice, spinal cords samples from 19-day-old Caspr
knockout mice treated with PNGase F showed dramatically
reduced neurofascin 155H and no band representing neurofas-
cin 155H’ was observed following PNGase F treatment (arrow).
Neurofascin 155L’ appears modestly reduced. The Magic Mark
Western Protein standard (M) revealed the shift in molecular
mass following treatment with PNGase F. CP = Caspr;
= untreated; P = PNGase F treated; KO = knockout;
WT = wild-type; Nfasc = neurofascin; ERK2 = extracellular
signal-regulated kinase 2.
Table 3 Neurofascin 155H’ and neurofascin 155L’ in the CST knockout spinal cord
Age Wild-type (n) SD (%) Knockout (n) SD (%) P Reduction (%)
Neurofascin 155H’, % of wild-type
15 days 100 (3) 14.40 50.1 (4) 32.30 0.009 49.9
30 days 100 (3) 11.30 55.0 (4) 23.50 0.005 45
4 months 100 (2) 8.40 34.4 (2) 28.10 0.019 65.6
Neurofascin 155L’, % of wild-type
15 days 100 (3) 22.90 77.5 (4) 26.90 0.249 0
30 days 100 (3) 14.40 91.2 (4) 20.80 0.515 0
4 months 100 (2) 11.60 87.1 (2) 9.70 0.342 0
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Figure 8 The pattern of neurofascin 155H’ and neurofascin 155L’ is altered in multiple sclerosis plaques. (A) Following the extended
electrophoresis protocol, clearly delineated neurofascin 155L was not observed in non-multiple sclerosis (A1 and A2) or normal-appearing
white matter-multiple sclerosis (A1 and A3) samples but was observed in multiple sclerosis plaque samples (black stars). (B) Following
PNGase F treatment, no clearly delineated neurofascin 155L’ band was observed in either the non-multiple sclerosis or normal-appearing
white matter-multiple sclerosis samples. In contrast, neurofascin 155L’ was clearly observed in the majority of multiple sclerosis brains
analysed (white stars). (C) The ratio of neurofascin 155H’/neurofascin 155L’ was significantly reduced in multiple sclerosis plaque samples
(n = 8; P50.006) compared to non-multiple sclerosis and normal-appearing white matter-multiple sclerosis samples (n = 7).
(D) Side-by-side analysis of PNGase F treated samples of normal-appearing white matter-multiple sclerosis and multiple sclerosis plaque
samples from the same donors shows neurofascin 155L’ only in the plaque samples. It is noteworthy that the pattern of neurofascin 155H’
and neurofascin 155L’ is similar between inactive (#243) and active (#137) plaque samples. Additionally, neurofascin 186’ was frequently
not observed in multiple sclerosis plaque samples. The commonly used loading control proteins b-actin, glyceraldehyde 3-phosphate
dehydrogenase and extracellular signal-regulated kinase 2 are shown and demonstrate a lack of autolysis within the samples.
= untreated; P = PNGase F treated; NM or NAWM = normal appearing white matter from multiple sclerosis donor; M = Magic Mark XP
Protein Standard; MS = multiple sclerosis; Nfasc = neurofascin; ERK2 = extracellular signal-regulated kinase 2; GAPDH = glyceraldehyde
3-phosphate dehydrogenase. P50.05.
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Interestingly, samples from donors #164 and #224 revealed
an apparent reduction of neurofascin 155H, which may have
increased the visibility of neurofascin 155L. Thus it was postulated
that the apparent absence of neurofascin 155L in some multiple
sclerosis plaque (donors #168 and 73), normal-appearing white
matter-multiple sclerosis (donor #235) and non-multiple sclerosis
(donor #5) samples resulted from an intense, bulky neurofascin
155H band which was obscuring a less intense neurofascin 155L
band, as is the case with rodent (compare 30-day-old wild-type to
30-day-old knockout in Figs 3A, B). To test this hypothesis,
non-multiple sclerosis, normal-appearing white matter-multiple
sclerosis and multiple sclerosis plaque samples were treated with
PNGase F. Non-multiple sclerosis and normal-appearing white
matter-multiple sclerosis samples (donors #5 and 235; Fig. 8B)
showed a prominent neurofascin 155H’ band with a faint
shadow-like neurofascin 155L’ band that was continuous with
the neurofascin 155H’ band. Additionally, the remaining
non-multiple sclerosis (donor #2) and normal-appearing white
matter-multiple sclerosis (donor #237) samples showed a similar
pattern. All multiple sclerosis plaque samples treated with PNGase
F yielded a neurofascin 155H’ band while five of the eight samples
(Fig. 8B, donors #137, 216, 224; see #243 in Fig. 8D, and #164
not shown) revealed a clearly delineated neurofascin 155L’ band.
To compare quantitative changes in the neurofascin 155H’ and
neurofascin 155L’ pattern, a densitometric ratio of neurofascin
155H’ to neurofascin 155L’ was determined for each sample.
This ratio was utilized instead of direct comparisons to account
for the variability that is inherent in human tissue sampling. As
shown in Fig. 8C, the ratio of neurofascin 155H’ to neurofascin
155L’ was significantly reduced in the multiple sclerosis plaques
(n = 8; 4.2 3.5, P50.006) compared to the non-multiple sclerosis
and normal-appearing white matter-multiple sclerosis samples
(n = 7; 14.2 6.6).
In addition to the decrease in the neurofascin 155H’/neurofas-
cin 155L’ ratio in multiple sclerosis samples, alterations in the
levels of neurofascin 186 were also observed. Although neurofas-
cin 186 was always detected in the non-multiple sclerosis samples,
one (donor #216) of five normal-appearing white matter-multiple
sclerosis samples failed to reveal neurofascin 186 while three
(donors # 137, 216, and 224) of eight multiple sclerosis samples
yielded no neurofascin 186 (Figs 8A1, 8A2 and 8A3). Importantly,
multiple sclerosis donor #164 presented both neurofascin 155L
and neurofascin 186 (Fig. 8A1 and 8A3), demonstrating that the
presence of neurofascin 155L is not dependent on the absence of
neurofascin 186; and suggesting that neurofascin 155L is a not a
breakdown product of neurofascin 186. Also note that neurofas-
cin 186 is present in the normal-appearing white matter-multiple
sclerosis samples from donors #243 and #137 (Fig. 8D) but is
absent in the plaques samples from these same donors, suggest-
ing that the absence of neurofascin 186 is not the result of
post-mortem autolysis and is a multiple sclerosis plaque-specific
alteration. Further supporting the absence of significant
post-mortem autolysis, no changes in the levels of b-actin, extra-
cellular signal-regulated kinase 2 or glyceraldehyde 3-phosphate
dehydrogenase were observed between normal-appearing white
matter-multiple sclerosis and multiple sclerosis plaque samples
from the same donors (Fig. 8D). Additionally, there was no
correlation between the absence of neurofascin 186 and the
length of time between death and tissue collection (Table 1), in
agreement with a previous study demonstrating preservation of
nodal and paranodal proteins up to 24 hours post-mortem
(Howell et al., 2006).
Discussion
In the absence of sulphatide, paranodes appear structurally normal
during development but deteriorate with age (Marcus et al.,
2006). In the current study, quantitative analysis revealed that
neurofascin 155 accumulated in the paranode in the absence of
sulphatide; however, the number of anti-neurofascin-positive
paired clusters in the spinal cord of the CST knockout mice was
reduced by 50 and 90% at 15 and 30 days of age, respectively.
Western blot analyses indicated that total levels of neurofascin
155 in the CST knockout mice are reduced 40% at both 15
and 30 days of age. Therefore, the significant reduction of neu-
rofascin 155 clustering observed at 15 days of age may be a
consequence of reduced neurofascin 155 expression; however,
decreased protein levels alone do not provide adequate explana-
tion for the continued reduction of paired paranodal clusters of
neurofascin 155 by 30 days of age. These differences suggest a
relationship between sulphatide and maintenance and localization
of neurofascin 155 at the paranode. In contrast, sulphatide is not
required for initial paranode formation (Marcus et al., 2006). The
mechanistic differences between paranode development and
maintenance are yet to be determined.
Extended electrophoresis revealed the presence of a neurofascin
155 doublet. These bands have been termed neurofascin 155H
and neurofascin 155L to reflect their relative molecular masses.
The 40% reduction in neurofascin 155 at both 15 and 30
days of age can be solely attributed to the reduction of neurofas-
cin 155H, as levels of neurofascin 155L remain unchanged in the
CST knockout mice. The observation of neurofascin 155H at the
paranode along with the specific reduction of neurofascin 155H in
mice that exhibit paranodal instability is consistent with neurofas-
cin 155H, but not neurofascin 155L, being a paranodal protein
required for preservation of paranodal integrity. Although the
loss of neurofascin 155H correlates with paranodal instability in
the sulphatide and Caspr null mice, the possibility persists that
the loss of neurofascin 155H is the result of paranodal breakdown,
rather than its cause.
Together, these findings demonstrate that sulphatide is essential
for paranodal integrity due to its role in maintaining established
paranodal protein domains. Ishibashi et al. (2002) reported a loss
of both nodal sodium and juxtaparanodal potassium channel clus-
ters in the CST knockout mice; however, this loss was not signif-
icant until 6 weeks of age. The reduction of neurofascin 155
paranodal clusters is significant as early as 15 days of age, while
the paranodal structure is normal (Marcus et al., 2006), suggesting
that the reduction and loss of neurofascin 155 clusters from
the myelin paranode precedes, and may facilitate, neuronal
deterioration.
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What is the difference between
neurofascin 155H and
neurofascin 155L?
Possible sources for neurofascin 155H and neurofascin 155L
include products of different genes, splice variants of the same
gene, or the same amino acid sequence with differential post
translational modifications. Utilizing the CNP-Cre;Nfascflox mice
(Pillai et al., 2009) this study demonstrated that neurofascin
155H and neurofascin 155L are products of the same gene (the
Nfasc gene); however, it remains to be determined whether neu-
rofascin 155H and neurofascin 155L differ according to amino acid
sequence and/or post-translational modifications.
The production of multiple splice variants is consistent with the
current understanding of the Nfasc gene as it produces at least
three proteins (Davis et al., 1996; Basak et al., 2007) and as many
as 50 transcripts (Hassel et al., 1997), lending validity to the idea
that neurofascin 155H and neurofascin 155L are distinct isoforms
of the Nfasc gene. However, it is also plausible that neurofascin
155H and neurofascin 155L consist of identical amino acid
sequences and that their molecular mass difference results from
varying post-translational modifications. Maier et al. (2005)
reported the observation of a neurofascin 155 doublet and specu-
lated that variable glycosylation may account for this observation.
Here, it has been shown that N-linked deglycosylation of neuro-
fascin 155H and neurofascin 155L does not result in the formation
of a single anti-neurofascin band. Thus, the difference between
neurofascin 155H and neurofascin 155L is not simply differential
N-linked glycosylation. Analyses with the AlphaEase software indi-
cated that removal of N-linked glycans with PNGase F resulted in
shifts of 12 and 17 kDa, respectively, for neurofascin 155H to
neurofascin 155H’ and neurofascin 155L to neurofascin 155L’ in
animals 3 months of age and older. This difference suggests that
neurofascin 155L either maintains N-linked glycans at more sites
than neurofascin 155H or that the carbohydrates on neurofascin
155L are more extensive than those attached to neurofascin
155H.
Other modifications that have been reported for neurofascin
186, the neuronal isoform of the neurofascin gene, include phos-
phorylation (Garver et al., 1997; Tuvia et al., 1997), O-linked
glycosylation (Volkmer et al., 1992) and palmitoylation (Ren and
Bennett, 1998). While Volkmer et al. (1992) have shown that
O-linked glycosylation does not occur in neurofascin 155, it
remains to be determined whether neurofascin 155H or neurofas-
cin 155L are palmitoylated or phosphorylated. Following N-linked
deglycosylation, neither neurofascin 155H nor neurofascin 155L,
at any age analysed, migrated at 132 kDa, which is the predicted
mass of neurofascin 155 based on amino acid sequence, suggest-
ing that differences other than the published amino acid sequence
for neurofascin 155 and N-linked glycosylation contribute to the
molecular mass of neurofascin 155H and neurofascin 155L.
However, it cannot be ruled out that the deglycosylated proteins
may migrate anomalously in the gel, thus accounting for migration
above 132 kDa.
In Fig. 4A, neurofascin 155L appears to emerge from the
shadow-like band below neurofascin 155H with increasing age.
This apparent emergence suggests that neurofascin 155L is a deriv-
ative of neurofascin 155H; however, treatment with PNGase F
indicates that even at 14 days of age, when the two bands appar-
ently migrate together, neurofascin 155H’ and neurofascin 155L’
represent distinct protein populations. Figure 4B shows, particu-
larly following deglycosylation, that levels of neurofascin 155H’
decrease between 27 days and 3 months of age with a corre-
sponding increase in neurofascin 155L, suggesting that neurofas-
cin 155L could be a post-translational product of neurofascin
155H. However, in opposition to neurofascin 155L being derived
from neurofascin 155H, normal levels of neurofascin 155L’ are
maintained in the absence of neurofascin 155H’ in the aged CST
knockout mice, suggesting that levels of neurofascin 155L’ are not
dependent on the presence of neurofascin 155H’. Alternatively,
neurofascin 155L could be highly stable, such that the loss of
neurofascin 155H would have minimal effect on levels of neuro-
fascin 155L. This supposition is not supported by the recent report
that disruption of the Nfasc gene in the oligodendrocytes of
33-day-old mice results in the gradual loss of neurofascin 155
and complete loss within 60 days (Pillai et al., 2009). These find-
ings demonstrate that the stability of all oligodendrocyte-derived
Nfasc gene products is less than two months. Longer stability
would be required for the maintenance of neurofascin 155L in
the absence of neurofascin 155H, as is observed in the aged
CST knockout mice, since neurofascin 155H’ is lost as early as
3 months of age and neurofascin 155L is maintained through
15 months of age (unpublished observation). The possibility
cannot be excluded, however, that in the aged CST knockout
mice neurofascin 155H is rapidly converted into neurofascin
155L, precluding detection of neurofascin 155H or neurofascin
155H’ by western blot analysis.
Hassel and colleagues (1997) identified a fifth fibronectin III-like
domain in the Nfasc gene of chicken and rat after the original
report that only four fibronectin III-like domains were present
(Volkmer et al., 1992). This domain was also observed in cDNA
clones and, unlike the other fibronectin III-like domains, is
expressed as either a half (one exon) or a whole (two exons)
domain. The whole fifth fibronectin III-like domain is expressed
with the mucin-like domain, which is specific to neurofascin 186.
It is unclear whether or not this fifth fibronectin III-like domain is
expressed in known neurofascin proteins (Tait et al. 2000; Koticha
et al., 2005). The two halves of the fifth fibronectin III-like domain
are 5 kDa each and analysis with the NetNGlyc 1.0 Server indi-
cates two potential sites of N-linked glycosylation for the first half
and one potential site for the second half. It is interesting to con-
sider that either half of this domain may account for the observed
differences in size between neurofascin 155H and neurofascin
155L.
Are neurofascin 155H and neurofascin
155L functionally distinct?
The functional significance of differential glycosylation of neuro-
fascin 155H and neurofascin 155L is unknown. Since glycosylation
is a prime regulator of protein functions such as protease activity
(Van den Steen et al., 2001), intracellular trafficking (Yan et al.,
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2008), protein binding (Milev et al., 1995; Zhou et al., 2008) and
stability (Buck et al., 2007; Goa and Nehta, 2007; Li et al., 2007),
neurofascin 155H and neurofascin 155L may have distinct func-
tions related to their different states of glycosylation, including
potential interactions with contactin and/or Caspr; however, this
remains to be determined.
The only recognized function of neurofascin 155 is the binding
of neuronal contactin at the paranode (Tait et al., 2000; Gollan
et al., 2003; Bonnon et al., 2007). At an age when neurofascin
155H’, but not neurofascin 155L’, is detected (7 days of age; Fig.
4B), anti-neurofascin reactive paranodes are prevalent (Fig. 4C)
indicating that neurofascin 155H is a myelin paranodal protein
expressed early in the process of myelination. In contrast, neuro-
fascin 155L’ is not detected until the end of the second week of
life and continues to increase through at least 5 months of age,
suggesting that neurofascin 155L is not involved in the onset of
myelination. It cannot be concluded, however, that neurofascin
155H is the form that binds contactin or that neurofascin 155L
is not a paranodal protein involved in mediating myelin-axon inter-
actions. Interestingly, Maier et al. (2005), who detected an
anti-neurofascin doublet in the vicinity of 155 kDa, reported that
the lower band of the doublet is not detected in pure cultures of
oligodendrocytes, suggesting that oligodendrocyte-axon interac-
tion is a prerequisite for expression of the lower component of
the doublet, which is likely to be neurofascin 155L.
Neurofascin 155H and neurofascin 155H’ are virtually absent in
4-month-old CST knockout mice indicating that sulphatide is
required for long term maintenance of this protein. One possible
explanation for the loss of neurofascin 155H lies with the concept
of membrane rafts (Harder and Simons, 1997), which are small,
dynamic membrane domains enriched in cholesterol and sphingo-
lipids (reviewed by Dupree and Pomicter, 2009). Sulphatide, a
sphingolipid, is enriched in myelin fractions containing putative
raft proteins (Arvanitis et al., 2005) such as fyn (Krämer et al.,
1999), flotillin-1 (Salzer and Prohaska, 2001) and caveolin
(Sargiacomo et al., 1993); and neurofascin 155 has been impli-
cated as a raft protein (Maier, 2007; Schafer et al., 2004).
Therefore, the absence of sulphatide may result in abnormal raft
formation facilitating neurofascin 155H instability at the myelin
paranode. This is consistent with recent evidence implicating a
role for membrane rafts in regulating protease activity
(Abad-Rodriguez et al., 2004; Bae et al., 2008). It is interesting
that the Caspr knockout tissue reveals a decrease in neurofascin
155H and neurofascin 155H’. Since receptor–ligand binding, such
as occurs in the paranode between paranodal neurofascin and
neuronal contactin:Caspr (Tait et al., 2000; Gollan et al., 2003;
Bonnon et al., 2007), may induce raft formation (Subczynski and
Kusumi, 2003), a disruption of the myelin-axon junction may also
result in neurofascin 155H instability as a consequence of impaired
raft structure in the Caspr knockout mice.
Neurofascin 155L is variably
glycosylated with age
An increasingly intense, age-dependent shadow-like band
attached to and just beneath the band labelled ‘neurofascin
155H’ shown in Fig. 4A has been labelled ‘neurofascin 155H&L’
in later figures to denote the supposition that neurofascin 155H’
and neurofascin 155L’ are derived from this band plus the
shadow-like band (Figs 5A, 5B, 6A and 7). Presumably, neurofas-
cin 155L migrates with/immediately below neurofascin 155H in
younger animals (compare Fig. 4A and B; 14, 21 and 27 days
of age, as well as the first four pairs of lanes in Fig. 6A). At all
ages, the shift from neurofascin 155H to neurofascin 155H’ is
12 kDa while the shift from the shadow-like band to distinct
neurofascin 155L’ is 22 kDa in younger animals and 17 kDa
for neurofascin 155L in older animals, suggesting that neurofascin
155L is variably glycosylated with age. Specifically, neurofascin
155L may become less glycosylated with age, accounting for the
gradual, age-related transition from the shadow-like band below
neurofascin 155H in younger animals to the emergence of the
distinct neurofascin 155L band observed in older animals
(Fig. 4A). The same conclusion is suggested by Fig. 6A, where
neurofascin 155L is not observed in the 15 or 30-day-old
wild-type untreated lanes but neurofascin 155L’ is observed fol-
lowing PNGase F treatment. Age-related changes in glycosylation
is documented in adhesion proteins of immune cells (Daniels et al.,
2002), epithelial cells (Wang et al., 2008) and nervous system
cells (Edelman, 1985). Based on these observations, it is reason-
able to propose that neurofascin 155H’ is deglycosylated neuro-
fascin 155H, that neurofascin 155L’ is deglycosylated neurofascin
155L, and that results regarding neurofascin 155H’ and neurofas-
cin 155L’ can provide information regarding neurofascin 155H and
neurofascin 155L.
Levels of both oligodendrocyte and
neuronal neurofascin are altered
in multiple sclerosis
In multiple sclerosis plaque samples, the ratio of neurofascin
155H’/neurofascin 155L’ is significantly reduced compared to
non-multiple sclerosis and normal-appearing white matter-multiple
sclerosis. This finding is intriguing in light of the significant reduc-
tion observed for neurofascin 155H’ in the CST knockout model in
the presence of unaltered levels of neurofascin 155L’. In both
multiple sclerosis plaques and in CST knockout mice, the pattern
of neurofascin 155H’ and neurofascin 155L’ is disrupted, concur-
rent with paranodal deterioration that precedes axonal pathology.
It remains to be determined, however, in both human and mouse
models, whether disruption of neurofascin 155H and/or neurofas-
cin 155L causes or results from paranodal deterioration.
In this study, the multiple sclerosis samples were categorized
either as active or inactive based on the level of cellularity
within the harvested plaque. Neurofascin 155L’ was observed in
one of three active (donor #137) and four of five inactive (donors
#224, 164, 216, 243) plaques suggesting that the pathological
event that results in a reduced ratio of neurofascin 155H’ to neu-
rofascin 155L’ is initiated during active myelin deterioration. The
presence of clearly delineated neurofascin 155L’ in inactive pla-
ques is also consistent with the idea that neurofascin 155L’ is a
product of oligodendrocytes (although axons cannot be ruled out
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as a source), as few other cell types are present in inactive plaques
(Lassmann et al., 1998; Mycko et al., 2003). Neurofascin 155L’ as
a product of oligodendrocytes is consistent with the rodent find-
ings since mice that exhibit a disruption in the neurofascin gene in
oligodendrocytes are incapable of synthesizing neurofascin 155L.
It is intriguing that the neuronal form of neurofascin, neurofas-
cin 186, is less frequently observed in multiple sclerosis plaque
samples compared to non-multiple sclerosis and normal-appearing
white matter-multiple sclerosis samples. The reduced ability to
detect neurofascin 186 in multiple sclerosis is particularly interest-
ing in light of the findings of Mathey et al. (2007) who reported
that neurofascin antibodies, derived from serum of multiple scle-
rosis patients, selectively target the node of Ranvier, the specific
location of neurofascin 186 (Davis et al., 1996; Poliak and Peles,
2003), resulting in the recruitment of complement, axonal degen-
eration, and exacerbated pathology in a mouse model. Therefore,
the inability to detect neurofascin 186 in some normal-appearing
white matter-multiple sclerosis and multiple sclerosis plaque sam-
ples is consistent with the early axonal degeneration that occurs in
multiple sclerosis.
In conclusion, the present study demonstrates an essential role
for sulphatide in maintaining neurofascin 155 at the myelin para-
node and introduces the existence of two forms of neurofascin
155—neurofascin 155H and neurofascin 155L—that exhibit differ-
ential developmental expression and variable stability in the
absence of sulphatide. Moreover, neurofascin 155H is concen-
trated at the myelin paranode and is progressively lost from
both the paranode and the CNS concomitantly with structural
deterioration of the paranode. Similarly, the loss of paranodal
integrity observed in multiple sclerosis (Suzuki et al., 1969;
Howell et al., 2006) coincides with a significant alteration in the
pattern of neurofascin 155H’ and neurofascin 155L’. Determining
the consequence of this altered pattern of expression in multiple
sclerosis plaques will be an important step in understanding the
pathological mechanisms that underlie CNS degeneration.
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